TY - JOUR
T1 - Emerging Nanotechnology for Treatment of Alzheimer’s and Parkinson’s Disease
AU - Li, Amanda
AU - Tyson, Joel
AU - Patel, Shivni
AU - Patel, Meer
AU - Katakam, Sruthi
AU - Mao, Xiaobo
AU - He, Weiwei
N1 - Funding Information:
WH thanks the support from the National Natural Science Foundation of China (51772256) and the Program for Zhongyuan Leading Talents of Science and Technology Innovation in Henan Province (204200510016).
Publisher Copyright:
© Copyright © 2021 Li, Tyson, Patel, Patel, Katakam, Mao and He.
PY - 2021/5/25
Y1 - 2021/5/25
N2 - The prevalence of the two most common neurodegenerative diseases, Parkinson’s disease (PD) and Alzheimer’s Disease (AD), are expected to rise alongside the progressive aging of society. Both PD and AD are classified as proteinopathies with misfolded proteins α-synuclein, amyloid-β, and tau. Emerging evidence suggests that these misfolded aggregates are prion-like proteins that induce pathological cell-to-cell spreading, which is a major driver in pathogenesis. Additional factors that can further affect pathology spreading include oxidative stress, mitochondrial damage, inflammation, and cell death. Nanomaterials present advantages over traditional chemical or biological therapeutic approaches at targeting these specific mechanisms. They can have intrinsic properties that lead to a decrease in oxidative stress or an ability to bind and disaggregate fibrils. Additionally, nanomaterials enhance transportation across the blood-brain barrier, are easily functionalized, increase drug half-lives, protect cargo from immune detection, and provide a physical structure that can support cell growth. This review highlights emergent nanomaterials with these advantages that target oxidative stress, the fibrillization process, inflammation, and aid in regenerative medicine for both PD and AD.
AB - The prevalence of the two most common neurodegenerative diseases, Parkinson’s disease (PD) and Alzheimer’s Disease (AD), are expected to rise alongside the progressive aging of society. Both PD and AD are classified as proteinopathies with misfolded proteins α-synuclein, amyloid-β, and tau. Emerging evidence suggests that these misfolded aggregates are prion-like proteins that induce pathological cell-to-cell spreading, which is a major driver in pathogenesis. Additional factors that can further affect pathology spreading include oxidative stress, mitochondrial damage, inflammation, and cell death. Nanomaterials present advantages over traditional chemical or biological therapeutic approaches at targeting these specific mechanisms. They can have intrinsic properties that lead to a decrease in oxidative stress or an ability to bind and disaggregate fibrils. Additionally, nanomaterials enhance transportation across the blood-brain barrier, are easily functionalized, increase drug half-lives, protect cargo from immune detection, and provide a physical structure that can support cell growth. This review highlights emergent nanomaterials with these advantages that target oxidative stress, the fibrillization process, inflammation, and aid in regenerative medicine for both PD and AD.
KW - Alzheimer’s disease
KW - Parkinson’s disease
KW - nanotechnology/nanomaterials
KW - nanozymes
KW - oxidative stress
UR - http://www.scopus.com/inward/record.url?scp=85107407878&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107407878&partnerID=8YFLogxK
U2 - 10.3389/fbioe.2021.672594
DO - 10.3389/fbioe.2021.672594
M3 - Review article
C2 - 34113606
AN - SCOPUS:85107407878
SN - 2296-4185
VL - 9
JO - Frontiers in Bioengineering and Biotechnology
JF - Frontiers in Bioengineering and Biotechnology
M1 - 672594
ER -